Involvement of Galectin-9/TIM-3 Pathway in the Systemic Inflammatory Response in Early-Onset Preeclampsia

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Miko, Eva ^a,b   Meggyes, Matyas ^a,b   Bogar, Barbara ^a   Schmitz, Nora ^a   Barakonyi, Aliz ^a,b   Varnagy, Akos ^b   Farkas, Balint ^b   Tamas, Peter ^b   Bodis, Jozsef ^b   Szekeres Bartho, Julia ^a,b   Illes, Zsolt ^c,d   Szereday, Laszlo ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; ECALECTIN; MUCIN 3;

ADULT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; MOLECULAR MODEL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHENOTYPIC VARIATION; PREECLAMPSIA; PREGNANT WOMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE SUBPOPULATION;

ADULT; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; GALECTINS; HUMANS; INFLAMMATION; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MEMBRANE PROTEINS; PHENOTYPE; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84880972150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071811     Document Type: Article

References (44)

1. Ghulmiyyah L, Sibai B, (2012) Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 36: 56-59. doi:10.1053/j.semperi.2011.09.011. PubMed: 22280867.
2. Duley L, (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33: 130-137. doi:10.1053/j.semperi.2009.02.010. PubMed: 19464502.
3. Roberts JM, Pearson G, Cutler J, Lindheimer M, (2003) Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 41: 437-445. doi:10.1161/01.HYP.0000054981.03589.E9. PubMed: 12623940.
4. Huppertz B, (2008) Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51: 970-975. doi:10.1161/HYPERTENSIONAHA.107.107607. PubMed: 18259009.
5. Roberts JM, Hubel CA, (2009) The two stage model of preeclampsia: variations on the theme. Placenta 30 (Suppl A):: S32-S37. doi:10.1016/j.placenta.2008.11.009. PubMed: 19070896.
6. Moffett-King A, (2002) Natural killer cells and pregnancy. Nat Rev Immunol 2: 656-663. doi:10.1038/nri886. PubMed: 12209134.
7. Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A, (2007) Inadequate tolerance induction may induce pre-eclampsia. J Reprod Immunol 76: 30-39. doi:10.1016/j.jri.2007.08.002.
8. Redman CW, Sargent IL, (2005) Latest advances in understanding preeclampsia. Science (New York, NY) 308: 1592-1594. doi:10.1126/science.1111726. PubMed: 15947178.
9. Hiby SE, Walker JJ, O'shaughnessy KM, Redman CWG, Carrington M, et al. (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 200: 957-965. doi:10.1084/jem.20041214. PubMed: 15477349.
10. Redman CWG, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, et al. (2012) Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 33 (Suppl):: S48-S54. doi:10.1016/j.placenta.2011.12.006. PubMed: 22217911.
11. Knight M, Redman CW, Linton EA, Sargent IL, (1998) Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 105: 632-640. doi:10.1111/j.1471-0528.1998.tb10178.x. PubMed: 9647154.
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005. doi:10.1056/NEJMoa055352. PubMed: 16957146.
13. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, et al. (2002) Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 186: 158-166. doi:10.1067/mob.2002.119176. PubMed: 11810103.
14. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, et al. (2010) Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLOS ONE 5: e13263. doi:10.1371/journal.pone.0013263. PubMed: 20948996.
15. Redman CWG, Sargent IL, (2003) Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review. Placenta 24 (Suppl A):: S21-S27. doi:10.1053/plac.2002.0930. PubMed: 12842410.
16. Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ, (2012) Preeclampsia: multiple approaches for a multifactorial disease. Dis Models Mechanisms 5: 9-18. doi:10.1242/dmm.008516. PubMed: 22228789.
17. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP, (2001) Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 86: 2505-2512. doi:10.1210/jc.86.6.2505. PubMed: 11397847.
18. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW, (1995) Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 102: 20-25. doi:10.1111/j.1471-0528.1995.tb09020.x. PubMed: 7833306.
19. Sakai M, Shiozaki A, Sasaki Y, Yoneda S, Saito S, (2004) The ratio of interleukin (IL)-18 to IL-12 secreted by peripheral blood mononuclear cells is increased in normal pregnant subjects and decreased in pre-eclamptic patients. J Reprod Immunol 61: 133-143. doi:10.1016/j.jri.2004.01.001. PubMed: 15063636.
20. Sargent IL, Borzychowski AM, Redman CWG, (2006) NK cells and human pregnancy--an inflammatory view. Trends Immunol 27: 399-404. doi:10.1016/j.it.2006.06.009. PubMed: 16843067.
21. Miko E, Szereday L, Barakonyi A, Jarkovich A, Varga P, et al. (2008) The role of invariant NKT cells in pre-eclampsia. Am J Reprod Immunol (New York, NY: 198960:: 118-126. doi:10.1111/j.1600-0897.2008.00603.x. PubMed: 18573130.
22. Miko E, Szereday L, Barakonyi A, Jarkovich A, Varga P, et al. (2009) Immunoactivation in preeclampsia: Vdelta2+ and regulatory T cells during the inflammatory stage of disease. J Reprod Immunol 80: 100-108. doi:10.1016/j.jri.2009.01.003. PubMed: 19395088.
23. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, et al. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536-541. doi:10.1038/415536a. PubMed: 11823861.
24. Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ, (2003) The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol 3: 454-462. doi:10.1038/nri1111. PubMed: 12776205.
25. He W, Fang Z, Wang F, Wu K, Xu Y, et al. (2009) Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation 88: 782-790. doi:10.1097/TP.0b013e3181b47f25. PubMed: 19920777.
26. Wang F, He W, Zhou H, Yuan J, Wu K, et al. (n.d.) The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol 250: 68-74. doi:10.1016/j.cellimm.2008.01.006. PubMed: 18353298.
27. Wang F, He W, Yuan J, Wu K, Zhou H, et al. (2008) Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol 19: 12-19. doi:10.1016/j.trim.2008.01.008. PubMed: 18346632.
28. Lee J, Su EW, Zhu C, Hainline S, Phuah J, et al. (2011) Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol Cell Biol 31: 3963-3974. doi:10.1128/MCB.05297-11. PubMed: 21807895.
29. Van de Weyer PS, Muehlfeit M, Klose C, Bonventre JV, Walz G, et al. (2006) A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun 351: 571-576. doi:10.1016/j.bbrc.2006.10.079. PubMed: 17069754.
30. Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, et al. (2012) Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLOS ONE 7: e40146. doi:10.1371/journal.pone.0040146. PubMed: 22792231.
31. Ju Y, Hou N, Meng J, Wang X, Zhang X, et al. (2010) T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 52: 322-329. doi:10.1016/j.jhep.2009.12.005. PubMed: 20133006.
32. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, et al. (2003) Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4: 1093-1101. doi:10.1038/ni987. PubMed: 14556005.
33. Naka EL, Ponciano VC, Cenedeze MA, Pacheco-Silva A, Câmara NOS, (2009) Detection of the Tim-3 ligand, galectin-9, inside the allograft during a rejection episode. Int Immunopharmacol 9: 658-662. doi:10.1016/j.intimp.2008.11.013. PubMed: 19100864.
34. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, et al. (2008) Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 205: 2763-2779. doi:10.1084/jem.20081398. PubMed: 19001139.
35. Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, et al. (2010) Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol (Baltimore, Md: 1950184:: 4696-4707. doi:10.4049/jimmunol.0903478. PubMed: 20351188.
36. Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, et al. (2010) HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 40: 2493-2505. doi:10.1002/eji.201040340. PubMed: 20623550.
37. Toldi G, Saito S, Shima T, Halmos A, Veresh Z, et al. (2012) The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25- FoxP3+ regulatory T cells in normal pregnancy and pre-eclampsia. Am J Reprod Immunol (New York, NY: 198968:: 175-180. doi:10.1111/j.1600-0897.2012.01145.x. PubMed: 22510013.
38. Saito S, Nakashima A, Shima T, Ito M, (2010) Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol (New York, NY: 198963:: 601-610. doi:10.1111/j.1600-0897.2010.00852.x. PubMed: 20455873.
39. Chabtini L, Mfarrej B, Mounayar M, Zhu B, Batal I, et al. (2013) TIM-3 regulates innate immune cells to induce fetomaternal tolerance. J Immunol (Baltimore, Md: 1950190:: 88-96. doi:10.4049/jimmunol.1202176. PubMed: 23180822.
40. Zhao J, Lei Z, Liu Y, Li B, Zhang L, et al. (2009) Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity. J Immunol (Baltimore, Md: 1950182:: 6618-6624. doi:10.4049/jimmunol.0803876. PubMed: 19414817.
41. Trotta R, Parihar R, Yu J, Becknell B, Allard J, et al. (2005) Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood 105: 3011-3018. doi:10.1182/blood-2004-10-4072. PubMed: 15604218.
42. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, et al. (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126: 458-465. doi:10.1111/j.1365-2567.2008.03027.x. PubMed: 19278419.
43. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941-5946. doi:10.1073/pnas.0601335103. PubMed: 16585503.
44. Jiang W, Chai NR, Maric D, Bielekova B, (2011) Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol (Baltimore, Md: 1950187:: 781-790. doi:10.4049/jimmunol.1100789. PubMed: 21666061.